LGT Fund Management Co Ltd. Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

LGT Fund Management Co Ltd. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 575 shares of the biopharmaceutical company’s stock after selling 83 shares during the period. LGT Fund Management Co Ltd.’s holdings in Regeneron Pharmaceuticals were worth $302,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 31 shares during the period. Activest Wealth Management increased its stake in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Finally, Curat Global LLC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $600.00 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,024.36. The company’s 50 day simple moving average is $572.12 and its 200 day simple moving average is $567.22. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company has a market capitalization of $63.59 billion, a P/E ratio of 15.12, a PEG ratio of 1.92 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the business earned $11.56 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research note on Monday, June 9th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Argus downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Jefferies Financial Group raised their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Saturday, September 27th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.